Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms

Fineline Cube Apr 2, 2026
Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms

Fineline Cube Apr 2, 2026
Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Fineline Cube Apr 1, 2026
Company Deals

Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market

Fineline Cube Feb 10, 2026

Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co.,...

Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Fineline Cube Feb 10, 2026

Nanjing Hanxin Pharmaceutical Technology Co., Ltd. has entered a licensing agreement with Amphastar Pharmaceuticals, Inc....

Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Fineline Cube Feb 10, 2026

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with...

Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Fineline Cube Feb 10, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive...

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu...

Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Fineline Cube Feb 10, 2026

Kintor Pharmaceutical Limited (HKG: 9939) has entered an exclusive marketing service agreement with Beijing Dekai...

Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with...

Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Fineline Cube Feb 10, 2026

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) has entered a strategic partnership with Shanghai RAAS...

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026

Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical...

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Fineline Cube Feb 9, 2026

Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European...

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Fineline Cube Feb 9, 2026

Novartis AG (NYSE: NVS) held a groundbreaking ceremony for a state-of-the-art global biomedical research center...

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced completion of patient enrollment for the registrational Phase III...

Company Drug

Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma

Fineline Cube Feb 9, 2026

Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Wins FDA Nod for US Pivotal Trial in Tricuspid Regurgitation

Fineline Cube Feb 9, 2026

Jenscare Scientific Co., Ltd. (HKG: 9877) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Hengrui Pharma’s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer

Fineline Cube Feb 9, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting...

Company Drug

Pfizer’s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion

Fineline Cube Feb 9, 2026

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted...

Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Fineline Cube Feb 9, 2026

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III...

Company Drug

InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials

Fineline Cube Feb 9, 2026

InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self-developed VAV1-targeting molecular glue degrader,...

Company Drug

Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China

Fineline Cube Feb 9, 2026

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication

Fineline Cube Feb 9, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that the National Medical Products Administration (NMPA)...

Posts pagination

1 … 23 24 25 … 645

Recent updates

  • Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms
  • China’s NMPA Unveils Ambitious “AI + Drug Regulation” Roadmap Through 2035
  • Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms
  • Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
  • Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms

Others

China’s NMPA Unveils Ambitious “AI + Drug Regulation” Roadmap Through 2035

Company Deals

Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms

Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.